FATE - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 26, 2026

4.0/10

Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Revenue is heavily reliant on collaboration agreements (Ono) and government grants, with no meaningful product sales revenue expected for several years.. Management expresses caution regarding future funding, highlighting the dependence on equity or debt financings and the uncertainty of obtaining them on favorable terms.. Multiple securities and derivative lawsuits are ongoing, alleging violations of federal securities laws and breach of fiduciary duties related to past disclosures and company actions.. Collaboration revenue decreased by 51.3% to $6.6 million from $13.6 million.

Top Concerns

!The company faces significant financial challenges, with substantial accumulated losses and negative operating cash flows, and anticipates continued losses for the foreseeable future.
!The company is actively pursuing research and development, with key initiatives focused on clinical trials and manufacturing of product candidates, despite inherent risks and uncertainties in drug development.
!Prior year impairment charges on long-lived assets and right-of-use assets totaling $14.7 million.
!Multiple securities and derivative lawsuits are ongoing, alleging violations of federal securities laws and breach of fiduciary duties related to past disclosures and company actions.
!The company has minimum annual payments of $0.4 million for exclusive license agreements, which are generally cancelable with notice.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

5.0/10

Management tone is cautiously measured.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

6.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

2.0/10

Overall risk profile shows regulatory approval and development risk as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

3.0/10

Segment health analysis.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.